Collateral sensitivity as a strategy against cancer multidrug resistance

详细信息	查看全文 | 推荐本文 |

• 作者：Kristen M. Pluchino^a ; ^b ; Matthew D. Hall^a ; Andrew S. Goldsborough^a ; Richard Callaghan^b ; Michael M. Gottesman^a ; ^{gottesmm@mail.nih.gov}
• 关键词：Multidrug resistance ; Collateral sensitivity ; P-glycoprotein ; MDR1-selective ; Verapamil ; MRP1
• 刊名：Drug Resistance Updates
• 出版年：2012
• 期刊代码：14_13687646
• 类别：bio
• 出版时间：February-April, 2012
• 卷：15
• 期：1-2
• 页码：98-105
• 文件大小：548 K

摘要

While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approximately 90%of treatment failure. Multidrug resistance (MDR), the simultaneous resistance to drugs that differ both structurally and mechanistically, often results from drug efflux pumps in the cell membrane that reduce intracellular drug levels to less than therapeutic concentrations. Expression of the MDR transporter P-glycoprotein (P-gp, MDR1, ABCB1) has been shown to correlate with overall poor chemotherapy response and prognosis. This review will focus on collateral sensitivity (CS), the ability of compounds to kill MDR cells selectively over the parental cells from which they were derived. Insights into CS may offer an alternative strategy for the clinical resolution of MDR, as highly selective and potent CS agents may lead to drugs that are effective at MDR cell killing and tumor resensitization. Four main mechanistic hypotheses for CS will be reviewed, followed by a discussion on quantitative and experimental evaluation of CS.